Topics / Oncology
Weekly issue
Oncology Papers of the Week
The top Oncology papers of the week: the 20 most important new papers of the past week, ranked by potential impact. A new issue comes out every Monday, covering the previous Monday-to-Sunday week.
- 1Positional Replication Fork Instability Drives PARP Inhibitor Cytotoxicity
Using CRISPR screens, we identify that loss of replication-coupled cohesin acetyltransferase ESCO2 confers PARPi hypersensitivity independently of homologous recombination deficiency.
- 2Molecular Profiling and Precision Oncology for Non-Small Cell Lung Cancer in Latin America: Unique Epidemiology, Persistent Barriers, and Paths Toward Equity
In this review, we discuss the unique molecular epidemiology of the region and the challenges of treatment implementation, focusing on the urgent need to integrate new technologies to ensure equitable access to precision oncology.
- 3Phytocannabinoids in Neurologic, Neuropsychiatric, Inflammatory, Pain, Cardiometabolic, Hepatic, Renal, and Neoplastic Disorders: Pharmacology, Clinical Evidence, and Translational Perspectives
This review integrates molecular pharmacology, pharmacokinetics, safety, and therapeutic evidence across neurologic, neuropsychiatric, inflammatory, pain, cardiovascular and metabolic, hepatic, renal, and neoplastic disorders.
- 4Tumor-colonizing Bifidobacterium Dentium Promotes Tumor Progression and Chemotherapy Resistance Via MMP3 and GABA-FOXA2-P-gp Axis
Here, we identify Bifidobacterium dentium (B. dentium ) as a tumor-associated bacterium enriched in fecal samples from patients with melanoma and colorectal cancer (CRC) and detectable in human melanoma and CRC tissues.
- 5Per- and Polyfluoroalkyl Substance Exposure and Breast Cancer Incidence in The Sister Study
We conducted a case-cohort study within the Sister Study that included 1,609 breast cancer cases and 2,269 subcohort participants.
Get papers like these the day they come out, not a week later.
Follow this category- 6In Situ CAR Engineering and Nanoparticle-mediated TREM2 Degradation for Macrophage Reprogramming in Malignant Ascites
Single-cell analysis of patient-derived PM and malignant tumour ascites reveals an approximately 90% enrichment of TREM2 -tumour-associated macrophages, which drive CD8 T cell dysfunction and tumour growth.
- 7The Transformation of Oncology Drug Development in China: Toward A New Phase of Innovation
We review regulatory reform and the 2015 to 2025 evolution of clinical development across small molecules, mAbs, multispecific antibodies, antibody-drug conjugates, and cell and gene therapies.
- 8Spatiotemporal Control of CAR-T Cell TNF Release Via Tumor-targeted Irradiation
Here we show that integrating the spatial precision of ionizing radiation with the biological specificity of CAR-T cells enables localized delivery of the inflammatory cytokine tumor necrosis factor (TNF).
- 9
- 10Risovalisib for PIK3CA-mutated Recurrent or Persistent Ovarian Clear Cell Carcinoma: A Single-arm, Multicentre, Phase 2 Trial
We aimed to evaluate the anti-tumour activity and safety of the PI3Kα inhibitor, risovalisib, for treatment of patients with recurrent or persistent PIK3CA-mutated ovarian clear cell carcinoma.
- 11Single-cell and Spatial Analysis of Inflammation-associated Resistance in Intrahepatic Cholangiocarcinoma
Computational cell-cell communication analysis predicted increased communication probabilities between iCAFs and SPINK1⁺ epithelial cells and between InfMp and CD4Tem cells in non-response tumors, nominating TNF-TLR2, HMGB1-TLR2, AGT-CYBB, and TNF-ICAM1 as candidate ligand-receptor associations.
- 12
- 13Tumor Metastasis Co-opts Liver Hematopoiesis to Promote Immunosuppression
In this study, we identify a distinct form of hepatic hematopoiesis driven by liver metastasis-associated hematopoietic stem cells (LM-HSCs).
- 14Amrecibart and Cenvacibart for The Prevention of Catheter-related Thrombosis (ROXI-CATH): A Double-blind, Randomised, Placebo-controlled, Phase 2 Trial
We evaluated the safety and efficacy of amrecibart and cenvacibart for preventing venous thromboembolism after PICC placement.
- 15Tumor Cells Hijack Coagulation Signaling to Enable Immune Escape and Metastatic Dissemination
Here, we identified the coagulation initiator tissue factor (F3) as a central regulator bridging tumor metastasis and immune evasion in gastric cancer (GC).
- 16Global Proposal for The TNM Staging System for Poorly Differentiated Thyroid Cancer
To develop a PDTC-specific staging system. This cohort study analyzed data from the International Aggressive Thyroid Cancer Collaborative Group (IATCCG), including surgically treated patients at 91 centers in 14 countries from January 1984 to January 2026.
- 17
- 18
- 19Origins and Heterogeneity of Colorectal Cancer
Here, we explore the relationship between the position of the cell-of-origin on the vertical crypt axis and the cell plasticity mechanisms co-opted and corrupted to escape homeostatic control. We consider how this influences clonal dynamics at the pre-cancer stage and initiates distinct carcinogenesis pathways engendering morphologically discrete precursor lesions.
- 20Soxataltinib, A Highly Selective CNS-penetrant RET Inhibitor Demonstrates Durable Activity in RET Fusion-positive Non-small Cell Lung Cancer Phase 2 Study
We conducted a multicenter, single-arm phase 2 study of soxataltinib, a highly selective CNS-penetrant RET inhibitor, in treatment-naïve (n=56) and previously treated patients (n=49) with advanced RET fusion-positive NSCLC.